NextCure Statistics

Total Valuation

NextCure has a market cap or net worth of $15.44 million. The enterprise value is -$34.58 million.

Market Cap	15.44M
Enterprise Value	-34.58M

Important Dates

The next estimated earnings date is Thursday, July 31, 2025, after market close.

Earnings Date	Jul 31, 2025
Ex-Dividend Date	n/a

Share Statistics

NextCure has 28.05 million shares outstanding. The number of shares has increased by 0.44% in one year.

Current Share Class	28.05M
Shares Outstanding	28.05M
Shares Change (YoY)	+0.44%
Shares Change (QoQ)	+0.00%
Owned by Insiders (%)	1.89%
Owned by Institutions (%)	30.73%
Float	20.65M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	0.27
P/TBV Ratio	0.28
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 10.26, with a Debt / Equity ratio of 0.10.

Current Ratio	10.26
Quick Ratio	9.78
Debt / Equity	0.10
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -63.94% and return on invested capital (ROIC) is -39.67%.

Return on Equity (ROE)	-63.94%
Return on Assets (ROA)	-36.39%
Return on Invested Capital (ROIC)	-39.67%
Return on Capital Employed (ROCE)	-86.43%
Revenue Per Employee	n/a
Profits Per Employee	-$1.15M
Employee Count	43
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -60.94% in the last 52 weeks. The beta is 1.08, so NextCure's price volatility has been similar to the market average.

Beta (5Y)	1.08
52-Week Price Change	-60.94%
50-Day Moving Average	0.43
200-Day Moving Average	0.91
Relative Strength Index (RSI)	63.70
Average Volume (20 Days)	140,710

Short Selling Information

The latest short interest is 317,029, so 1.13% of the outstanding shares have been sold short.

Short Interest	317,029
Short Previous Month	182,944
Short % of Shares Out	1.13%
Short % of Float	1.53%
Short Ratio (days to cover)	1.59

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-53.07M
Pretax Income	-61.28M
Net Income	-49.52M
EBITDA	-50.34M
EBIT	-53.07M
Earnings Per Share (EPS)	-$1.77

Full Income Statement

Balance Sheet

The company has $55.86 million in cash and $5.84 million in debt, giving a net cash position of $50.02 million or $1.78 per share.

Cash & Cash Equivalents	55.86M
Total Debt	5.84M
Net Cash	50.02M
Net Cash Per Share	$1.78
Equity (Book Value)	55.86M
Book Value Per Share	1.99
Working Capital	53.16M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$41.19 million and capital expenditures -$437,000, giving a free cash flow of -$41.63 million.

Operating Cash Flow	-41.19M
Capital Expenditures	-437,000
Free Cash Flow	-41.63M
FCF Per Share	-$1.48

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

NextCure does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.44%
Shareholder Yield	-0.44%
Earnings Yield	-320.77%
FCF Yield	-269.64%

Analyst Forecast

The average price target for NextCure is $3.50, which is 544.57% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$3.50
Price Target Difference	544.57%
Analyst Consensus	Strong Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	-23.54%

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1